AstraZeneca said on Wednesday that to its knowledge an ongoing investigation by Chinese authorities into the company's top ...

BMO Capital Markets analyst Etzer Darout in a note to investors said the insurance fraud probe represents a “headline risk” ...

Barclays analyst Emily Field says the selloff yesterday in shares of AstraZeneca (AZN) on a local news report that China’s investigation ...

Deutsche Bank upgraded AstraZeneca (AZN) to Hold from Sell with an unchanged price target of 10,500 GBp. The firm cites valuation for the ...

Tumors outside the central nervous system (CNS) did respond but the failure to shrink brain tumors took away TNG908’s raison d'etre. Tango has another MTA-cooperative PRMT5 inhibitor, TNG462, for ...

The AstraZeneca share price has fallen almost 25% since late August. Is there value on offer for investors after this huge ...

RBC raises Burberry to 'outperform' (sector perform) - price target 900 (650) pence Deutsche Bank Research cuts Vesuvius price target to 400 (470) pence - 'hold' RBC cuts Morgan Advanced Materials ...

The visit included tours of the Cambridge West Innovation District, Cambridge Graphene Centre, and AstraZeneca’s Discovery Centre (DISC); the pharmaceuticals giant will, through the new partnership, ...

Astra saw £14.4bn wiped off its value after Chinese media said dozens of managers were implicated in a scandal.

Key Takeaways AstraZeneca shares declined Tuesday after reports that senior executives in China were potentially implicated ...

(Alliance News) - AstraZeneca PLC on Tuesday took the rare step of addressing a sharp fall in the company's share price. Shares in the Cambridge-based pharmaceuticals company slumped 8.2% to 10,138.10 ...

AstraZeneca's (NASDAQ:AZN) selloff on Tuesday in response to reports that the company is facing a fraud investigation in ...